

**AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—COCATS 4 TASK FORCE 10: TRAINING IN CARDIAC CATHETERIZATION**

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speaker's Bureau</b>	<b>Ownership/ Partnership/ Principal</b>	<b>Personal Research</b>	<b>Institutional/ Organizational or Other Financial Benefit</b>	<b>Expert Witness</b>
Spencer B. King III (Chair)	Saint Joseph's Heart and Vascular Institute—Professor of Medicine (Emeritus), Emory University	<ul style="list-style-type: none"> <li>• Celanova Biosciences*</li> <li>• nContact Surgical</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Capricor (DSMB)</li> <li>• Duke University (DSMB)</li> <li>• Harvard Clinical Research Institute (DSMB)</li> <li>• Merck (DSMB)</li> <li>• Wyeth Nutrition (DSMB)</li> </ul>	<ul style="list-style-type: none"> <li>• Capricor</li> <li>• Duke University</li> <li>• Harvard Clinical Research Institute</li> <li>• Merck</li> <li>• Wyeth Pharmaceuticals</li> </ul>	None
Joseph D. Babb	East Carolina University Cardiovascular Sciences—Professor of Medicine	None	None	None	None	None	None
Eric R. Bates	University of Michigan Hospitals and Health Centers—Professor of Medicine	<ul style="list-style-type: none"> <li>• ABIM</li> <li>• AstraZeneca</li> <li>• Bristol-Meyers Squibb</li> <li>• Daiichi-Sankyo</li> <li>• Eli Lilly</li> <li>• Janssen Pharmaceuticals</li> <li>• Merck</li> <li>• Sanofi-aventis</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Harvard Clinical Research Institute (DSMB)</li> </ul>	<ul style="list-style-type: none"> <li>• AHA*</li> </ul>	None
Michael H. Crawford	University of California San Francisco Medical Center—Professor of Medicine, Chief of Clinical Cardiology	None	None	None	None	None	<ul style="list-style-type: none"> <li>• Defendant, malpractice, 2014</li> <li>• Plaintiff, malpractice, 2013</li> <li>• Plaintiff, 2012</li> </ul>
George D. Dangas	Mount Sinai Medical Center—Program Director, Interventional Cardiology	<ul style="list-style-type: none"> <li>• Abbott</li> <li>• AstraZeneca</li> <li>• Bayer</li> <li>• Boston Scientific</li> <li>• Covidien†</li> <li>• CSL Bhering</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Abbott*</li> <li>• Bristol-Meyers Squibb*</li> <li>• Daiichi-Sankyo*</li> <li>• Eli Lilly*</li> <li>• Lutonix*</li> </ul>	<ul style="list-style-type: none"> <li>• Abbott*</li> <li>• Accumetrics*</li> <li>• Amarex*</li> <li>• Cordis*</li> <li>• EV3*</li> <li>• Gilead Sciences*</li> </ul>	None

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
		<ul style="list-style-type: none"> <li>• GE Healthcare</li> <li>• Johnson &amp; Johnson†</li> <li>• Maya Medical*</li> <li>• Medtronic</li> <li>• Merck</li> <li>• Osprey Medical</li> <li>• Regado</li> <li>• Sanofi-aventis†</li> <li>• The Medicines Company</li> </ul>			<ul style="list-style-type: none"> <li>• Medtronic*</li> <li>• Sanofi-aventis*</li> <li>• The Medicines Company*</li> </ul>	<ul style="list-style-type: none"> <li>• IndeedMD*</li> <li>• Infraredx*</li> <li>• Lutonix*</li> <li>• Medtronic*</li> <li>• PLC*</li> <li>• The Medicines Company*</li> <li>• Tryton*</li> <li>• Volcano*</li> <li>• WI Gore</li> </ul>	
Michele D. Voeltz	Henry Ford Hospital—Director, Interventional Cardiology Fellowship Training Program	None	None	None	None	None	None
Christopher J. White	The Ochsner Clinical School, University of Queensland—Professor and Chairman of Medicine	<ul style="list-style-type: none"> <li>• Baxter BioSurgery*</li> <li>• Gardia</li> <li>• Neovasc</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• St. Jude Medical (DSMB)</li> </ul>	<ul style="list-style-type: none"> <li>• ACE*</li> <li>• NCDR-CARE Registry*</li> <li>• NCDR-PVD*</li> <li>• Neovasc</li> <li>• SCAI*</li> <li>• St. Jude Medical</li> <li>• Surmodics</li> </ul>	None

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

\* No financial benefit.

† Significant relationship.

ABIM = American Board of Internal Medicine; ACE = American Council on Exercise; AHA = American Heart Association; DSMB = Data Safety Monitoring Board; NCDR-CARE = National Cardiovascular Data Registry-Carotid Artery Revascularization and Endarterectomy Procedures; NCDR-PVD = National Cardiovascular Data Registry-Peripheral Vascular Disease; SCAI = Society for Cardiovascular Angiography and Interventions.